What Accro Bioscience does

Accro Bioscience is a clinical-stage biotechnology company founded in 2017 and headquartered at Suzhou BioBAY in China. The company is built around a regulated cell death (RCD) drug discovery platform that targets the intersection of programmed cell death mechanisms — necroptosis, pyroptosis, and ferroptosis — and inflammation, with the goal of breaking the cell-death-driven inflammatory cycle underlying immune-mediated inflammatory diseases. Its therapeutic candidates are orally administered small molecules, with the stated strategic intent of displacing injectable biologics in chronic inflammatory indications through improved convenience, dosing flexibility, and manufacturing economics.

The pipeline comprises three clinical-stage assets and a preclinical portfolio. The lead clinical asset AC-201 is a TYK2/JAK1 inhibitor that reported positive Phase 2 topline data in moderate-to-severe plaque psoriasis in May 2025, with data presented at EADV 2025, and is also advancing in non-infectious uveitis (Phase II NMPA IND cleared November 2024) and systemic lupus erythematosus. AC-101 is a RIPK2 inhibitor being developed for ulcerative colitis and Crohn's disease, with FDA IND clearance secured in December 2024 for a multi-regional Phase II study and first patient dosed in February 2025. AC-003 is a RIPK1 inhibitor being developed for acute graft-versus-host disease (aGVHD) and has been granted FDA Orphan Drug Designation. Preclinical programs target rheumatoid arthritis, atopic dermatitis, hidradenitis suppurativa, asthma, and COPD. The company holds 25+ issued patents across China, the US, Japan, Europe, and Korea covering its core targets and combination uses.

The business model is a pre-revenue, asset-by-asset regional out-licensing model combined with selective direct clinical development. The first major commercial transaction was an August 2025 exclusive Greater China licensing agreement with Fosun Pharma for AC-201, valued at an RMB 80 million upfront plus development and sales milestones plus tiered royalties. The company retains global rights for its other assets outside of Fosun's territory and is building US-based clinical development and business development capacity (office under construction in the New York/New Jersey area). Funding has come from venture rounds, with the most recent $50 million Series C in May 2026 led by OrbiMed and joined by TCGX, following a $12 million Series B+ in March 2025.

Name

Accro Bioscience

Legal name

Accro Bioscience (Suzhou) Limited

Website

https://accropeutics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Accro Bioscience is a clinical-stage biotechnology company developing orally administered small-molecule inhibitors that target regulated cell death pathways for immune-mediated inflammatory diseases. Founded in 2017 in Suzhou, China, the company has three clinical-stage assets and uses a regional out-licensing model.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals (immune-mediated inflammatory disease therapeutics)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Clinical-stage biotechnology
• Small molecule therapeutics
• Kinase inhibitors
• Regulated cell death
• Inflammatory disease drugs

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Licensing upfront and milestone payments: Receipt of upfront and near-term milestone payments from regional licensees (e.g., RMB 60M upfront + RMB 20M milestone from Fosun Pharma upon manufacturing tech transfer completion for AC-201).
2. Development and commercial milestone payments: Receipt of development milestone payments (up to RMB 76M from Fosun) tied to regulatory/development progress, plus commercial milestone payments and tiered double-digit royalties based on product sales in licensed regions.
3. Venture capital financing (pre-revenue clinical stage): Company is pre-revenue and clinical-stage; primary capital sources are equity financing rounds (Series A 2017, Series B 2021, Series B+ $12M in 2025, Series C $50M in 2026). Cash runway extended into H2 2026 post-Series B+.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Accro Bioscience discovers and develops oral small-molecule drug candidates that target regulated cell death pathways (necroptosis, pyroptosis, ferroptosis) for the treatment of immune-mediated inflammatory diseases. Its clinical-stage pipeline comprises AC-101 (RIPK2 inhibitor for inflammatory bowel disease/ulcerative colitis), AC-201 (TYK2/JAK1 inhibitor for plaque psoriasis, non-infectious uveitis, and other autoimmune indications), and AC-003 (RIPK1 inhibitor for aGVHD and IPF), developed from a proprietary Regulated Cell Death drug discovery platform.

Product overview

Accro Bioscience (Accropeutics) is a clinical-stage biotechnology company that operates a single unified proprietary drug discovery platform — the "Regulated Cell Death" platform targeting the "Cell Death - Inflammation" loop — which underpins a portfolio of three clinical-stage small-molecule drug candidates plus additional pre-clinical assets. The clinical-stage products are: AC-101 (selective RIPK2 inhibitor for inflammatory bowel disease/ulcerative colitis), AC-201 (selective TYK2/JAK1 pseudo-kinase inhibitor for plaque psoriasis and non-infectious uveitis, licensed to Fosun Pharma in Greater China), and AC-003 (selective RIPK1 inhibitor for acute Graft-versus-Host Disease, with FDA Orphan Drug Designation). The platform also supports multiple undisclosed pre-clinical assets in indications such as RA, AD, HS, asthma, and COPD. Accro owns global rights to all disclosed assets and holds 23+ issued patents across China, Japan, Korea, the U.S., and the EU.

Differentiator

Problem solved

Functional benefit

Products and services

• AC-101 (RIPK2 inhibitor) Novel, highly potent and selective oral small-molecule inhibitor of receptor-interacting protein kinase 2 (RIPK2) developed for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Inhibits NOD/RIPK2/NF-kB and MAPK signaling pathways; completed Phase I in Australia and China; in Phase Ib in China for UC; FDA-cleared for Phase II MRCT. Accro owns global rights.
• AC-201 (TYK2/JAK1 inhibitor)
• AC-003 (RIPK1 inhibitor)
• Confidential pre-clinical pipeline (RA, AD, HS, asthma, COPD) Multiple pre-clinical and lead-optimization stage assets targeting rheumatoid arthritis (RA), atopic dermatitis (AD), hidradenitis suppurativa (HS), asthma, and chronic obstructive pulmonary disease (COPD). Accro holds global rights.

Quantifiable outcome

• AC-201 Phase 2 PASI-75 response rates at Week 12: 8.1% (placebo), 31.4% (25mg BID), 74.3% (50mg BID), 59.5% (100mg QD) - all active doses statistically significant vs placebo (P<=0.012)
• +6 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Fosun Pharma (Shanghai Fosun Pharmaceutical, 600196.SH; 02196.HK)flagship - first major commercial license deal validating ac-201 assetOEM/ Whitelabel/ Licensing Partner · 29 August 2025Exclusive license agreement granting Shanghai Fosun Pharmaceutical Industrial Development Co. exclusive rights to develop, manufacture, and commercialize AC-201 (highly selective TYK2/JAK1 inhibitor) in Greater China (Chinese Mainland, Hong Kong SAR, Macau SAR). Accro retains global rights excluding Greater China. Deal economics: RMB 60M upfront + RMB 20M near-term milestone on manufacturing technology transfer completion (total RMB 80M), up to RMB 76M in development milestones, plus commercial milestone payments and tiered double-digit royalties on product sales in licensed regions.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Denali Therapeutics: Clinical-stage biotech developing brain-penetrant RIPK1 inhibitors (e.g., DNL747/DNL758) for neurodegenerative and inflammatory diseases. Directly comparable mechanism (RIPK1 kinase inhibition) to Accro's AC-003, and similar clinical-stage posture targeting regulated cell death biology.
• Connect Biopharma: China-origin clinical-stage biotech developing CBP-201 (IL-4Rα) and CBP-174 (TYK2) for atopic dermatitis and other inflammatory diseases. Comparable stage and China-rooted biotech profile developing oral/selective inflammatory disease therapeutics; TYK2 program directly comparable to Accro's AC-201.
• Zai Lab: Shanghai-based clinical/commercial-stage biotech with multiple autoimmune and inflammatory assets including licensed JAK1 and TYK2 inhibitors. Comparable China-rooted clinical-stage biotech executing global clinical development with a similar licensing/partnering business model for I&I indications.
• Ventyx Biosciences: Clinical-stage immunology biotech developing allosteric TYK2 (VTX958) and TYK2/JAK1 inhibitors for psoriasis, Crohn's disease, and other autoimmune indications. Direct mechanistic competitor to Accro's AC-201 with similar allosteric TYK2 design and comparable development stage.

Broad incumbents

• Bristol-Myers Squibb (BMS): Developer and marketer of Sotyktu (deucravacitinib), the first approved allosteric TYK2 inhibitor for plaque psoriasis. Direct competitor to Accro's AC-201 in psoriasis and other autoimmune indications, with established global commercial infrastructure and head-start in the TYK2 allosteric space.
• AbbVie: Markets Rinvoq (upadacitinib), a leading oral JAK1 inhibitor approved across rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. Represents the entrenched JAK1 standard-of-care that AC-201 must differentiate against in UC, PsO, and other I&I indications.
• Takeda Pharmaceutical: Developing zasocitinib (TAK-279), an allosteric TYK2 inhibitor acquired via the Nimbus Lakshmi transaction for psoriasis and other autoimmune diseases. Closest mechanistic competitor to Accro's AC-201 (also allosteric TYK2/JAK1), with substantially larger development and commercialization resources.
• Pfizer: Markets Cibinqo (abrocitinib, JAK1) for atopic dermatitis and Litfulo (ritlecitinib, JAK3/TEC) for alopecia areata, plus broader JAK franchise (Xeljanz). Direct competitor in the JAK-family oral autoimmune space that AC-201 and AC-101 will compete with on safety and convenience.
• Roche / Genentech: Developed and markets Xeljanz (tofacitinib) and is pursuing next-generation selective TYK2 programs; historically explored RIPK2 in inflammation. Comparable as an established pharma pursuing the same JAK/TYK2 and regulated-cell-death-adjacent pathways targeted by Accro's pipeline.

Regional players

• Innovent Biologics: Listed Chinese biotech (1801.HK) with a pipeline including TYK2 and JAK1 inhibitors in inflammatory diseases and broader immunology. Comparable as a Chinese clinical-stage developer pursuing oral selective immune kinase inhibitors; established commercial infrastructure in China that Accro lacks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/accro-bioscience

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accro Bioscience